Samir Saheb
University of Paris
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Samir Saheb.
Journal of Lipid Research | 2011
Alexina Orsoni; Samir Saheb; Johannes H.M. Levels; Geesje M. Dallinga-Thie; Marielle Atassi; Randa Bittar; Paul Robillard; Eric Bruckert; Anatol Kontush; Alain Carrié; M. John Chapman
Subnormal HDL-cholesterol (HDL-C) and apolipoprotein (apo)AI levels are characteristic of familial hypercholesterolemia (FH), reflecting perturbed intravascular metabolism with compositional anomalies in HDL particles, including apoE enrichment. Does LDL-apheresis, which reduces HDL-cholesterol, apoAI, and apoE by adsorption, induce selective changes in HDL subpopulations, with relevance to atheroprotection? Five HDL subpopulations were fractionated from pre- and post-LDL-apheresis plasmas of normotriglyceridemic FH subjects (n = 11) on regular LDL-apheresis (>2 years). Apheresis lowered both plasma apoE (−62%) and apoAI (−16%) levels, with preferential, genotype-independent reduction in apoE. The mass ratio of HDL2:HDL3 was lowered from ∼1:1 to 0.72:1 by apheresis, reflecting selective removal of HDL2 mass (80% of total HDL adsorbed). Pre-LDL-apheresis, HDL2 subpopulations were markedly enriched in apoE, consistent with ∼1 copy of apoE per 4 HDL particles. Large amounts (50-66%) of apoE-HDL were removed by apheresis, preferentially in the HDL2b subfraction (−50%); minor absolute amounts of apoE-HDL were removed from HDL3 subfractions. Furthermore, pre-β1-HDL particle levels were subnormal following removal (−53%) upon apheresis, suggesting that cellular cholesterol efflux may be defective in the immediate postapheresis period. In LDL-receptor (LDL-R) deficiency, LDL-apheresis may enhance flux through the reverse cholesterol transport pathway and equally attenuate potential biglycan-mediated deposition of apoE-HDL in the arterial matrix.
Atherosclerosis Supplements | 2014
Eric Bruckert; Samir Saheb; Juliette Roth Bonté; Carole Coudray-Omnès
Homozygous familial hypercholesterolaemia (HoFH) is a rare and severe hereditary lipid disorder that is typically associated with high serum levels of low-density lipoprotein cholesterol (LDL-C). Excessive exposure to high levels of LDL-C puts affected individuals at very high risk of premature onset coronary heart disease, and this considerably limits life expectancy. Although the clinical features and treatment of HoFH have been extensively researched, societal and socio-psychological impacts of the disease have not been reported to date. The current study was conducted to investigate the burden of disease and treatment from the patients perspective by means of semi-structured interviews with 24 HoFH patients. The findings of the survey indicate that HoFH represents a considerable burden for patients, not only due to physical signs and limitations caused by the disease but also a number of psychosocial factors, treatment-related issues and impact on their education and employment situation.
Journal of Clinical Lipidology | 2016
Hala Hussein; Samir Saheb; Martine Couturier; Marielle Atassi; Alexina Orsoni; Alain Carrié; Patrice Therond; Paul Robillard; Eric Bruckert; M. John Chapman; Anatol Kontush
BACKGROUND Familial hypercholesterolemia (FH) features elevated oxidative stress and accelerated atherosclerosis driven by elevated levels of atherogenic lipoproteins relative to subnormal levels of atheroprotective high-density lipoprotein (HDL). Small, dense HDL3 potently protects low-density lipoprotein (LDL) against proinflammatory oxidative damage. OBJECTIVE To determine whether antioxidative and/or anti-inflammatory activities of HDL are defective in FH and whether such defects are corrected by LDL apheresis. METHODS Antioxidative and antiinflammatory activities of HDL were evaluated as protection of reference LDL from oxidative stress and capacity to prevent accumulation of proinflammatory oxidised lipids, respectively. Lipid surface rigidity of HDL was assessed using a fluorescent probe. HDL components were measured by analytical approaches. Systemic oxidative stress was characterized as plasma 8-isoprostanes. RESULTS Pre-LDL-apheresis, FH patients (n = 10) exhibited elevated systemic oxidative stress (3.3-fold, P < 0.001) vs. sex- and age-matched normolipidemic controls (n = 10). Both antioxidative and antiinflammatory activity of HDL3 were impaired (up to -91%, P < 0.01) in FH. Sphingomyelin and saturated fatty acid contents were elevated in FH HDL3, resulting in enhanced lipid surface rigidity. The surface lipid content (phospholipids, free cholesterol) was reduced in FH (up to -15%, P < 0.001), whereas content of core lipids (cholesteryl esters, triglycerides) was elevated (up to +17%, P < 0.001). Molar apolipoprotein A-I content of HDL3 was subnormal in FH. A single LDL-apheresis session partially corrected (by up to 76%) deficient HDL antiatherogenic activities, attenuated systemic oxidative stress and partially normalised both the lipid composition and surface rigidity of HDL particles. CONCLUSIONS FH features elevated oxidative stress and deficient antioxidative and anti-inflammatory activities of small, dense HDL3; such functional deficiency is intimately linked to anomalies in lipid and protein composition, which may impair the capacity of HDL to acquire and inactivate oxidized lipids.
Atherosclerosis | 2015
Bruno Lefort; Samir Saheb; Eric Bruckert; Christine Giraud; Olivier Hequet; R. Hankard
Atherosclerosis | 2017
Eric Bruckert; Olga Kalmykova; Randa Bittar; Valérie Carreau; Sophie Béliard; Samir Saheb; David Rosenbaum; Dominique Bonnefont-Rousselot; Daniel Thomas; Corinne Emery; Babak Khoshnood; Alain Carrié
Archive | 2018
Sophie Bãliard-Lasserre; Samir Saheb; Philippe Moulin; A. Gallo; René Valãro; E. Bruckert
Atherosclerosis | 2018
Sophie Béliard; A. Gallo; Emilie Duchêne; Alain Carrié; Randa Bittar; M. John Chapman; Eric Bruckert; Samir Saheb
Atherosclerosis Supplements | 2010
M.J. Chapman; Paul Robillard; Alexina Orsoni; Samir Saheb; M. Atassi; Anatol Kontush; J. Lamont; Eric Bruckert
Atherosclerosis Supplements | 2010
Alexina Orsoni; Maryse Guerin; Martine Couturier; Geesje M. Dallinga-Thie; J.H.M. Levels; Samir Saheb; M. Atassi-Dumont; D. Bonnefont-Rousselot; Anatol Kontush; A. Carrié; Eric Bruckert; M.J. Chapman
Atherosclerosis Supplements | 2010
H. Hussein; Samir Saheb; Martine Couturier; M. Atassi; Alexina Orsoni; A. Carrié; Patrice Therond; S. Chantepie; Paul Robillard; Eric Bruckert; M.J. Chapman; Anatol Kontush